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Background: CCR5-delta32 heterozygous individuals are susceptible to HIV-1. However, it is not clear if there is a
relevant protective effect against transmission and a beneficial effect in terms of HIV progression which cannot be
attributed to CCR5 surface density alone. Therefore we investigated HIV-1 dependency factors (HDF) which might
be differently regulated in CCR5 wild type (WT) and CCR5-delta32 heterozygous individuals.
Methods: We examined CD34+ hematopoietic progenitor cells derived from bone marrow samples from 19
healthy volunteers, 12 individuals with CCR5 WT and 7 with heterozygous CCR5-delta32 deletion. Samples were
analyzed using a global gene expression oligonucleotide microarray (HG-U133plus 2.0, Affymetrix Inc.).
Results: A total of 205 genes were found with altered expression (3fold difference, present call rate of 75%,
p < 0.05) and 7 of these had a connection to HIV-1 pathogenesis. In 4 genes: TOP1, CXCR2, SREBF2, and TAP we
found a different regulation which was consistent with a supposed beneficial effect for CCR5-delta32 heterozygotes.
Conclusion: The CCR5-delta32 deletion is associated with other HDFs in HIV-1 pathogenesis as a possible
explanation for beneficial effects regarding the deletion leading to a variant expression profile in heterozygous
carriers of this mutation.
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The human immunodeficiency virus type 1 (HIV-1) ge-
nome encodes a rather small number of 15 proteins.
However, during infection and interaction with the tar-
get cells, the virus exploits multiple proteins of the host
for its replication. Alterations of expression or functional
changes based on genetic variances of critical genes are
called HIV-dependency factors (HDFs). They are re-
quired for infection or disease progression, influencing
the efficacy of HIV-1 transmission, viral load, and col-
lapse of the immune system. Understanding these HDFs
might play a key role in identifying new therapeutics
strategies against the infection [1].* Correspondence: gero.huetter@medma.uni-heidelberg.de
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reproduction in any medium, provided the orOne of the most prominent HDF is the association of
HIV-1 and the chemokine receptor CCR5. In combination
with CD4, CCR5 is required for internalization of the
viral genome. Up to date, over 70 mutations have been
described in the CCR5 gene including the intensively
studied 32 base pair deletion (CCR5-delta32) that intro-
duces a premature stop-codon into the CCR5 locus [2,3].
Interestingly, CCR5 is highly preferred from the virus
and people with a homozygous CCR5-delta32 deletion
gain a nearly complete protection from HIV-1 transmis-
sion. This is remarkable as CXCR4 is always expressed as
an alternative coreceptor in CCR5-deficient individuals
and most HIV positive patients harbor a small fraction of
CXCR4 using strains (X4 type) [4]. Therefore, CCR5
deficient individuals are frequently exposed against X4 but
hardly ever get infected. It is still not clear whether
this observation could only be explained by a presumed
selective disadvantage of X4 in the absence of CCR5 orLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 A selection of published surveys concerning possible clinical benefits (transmission or progression) of the
CCR5-delta32 heterozygous genotype
N= Study population Benefit tested Significance Reference
1427 HIV + vs. sero-negative control group Transmission P = 0.012 [8]
30 ESN Transmission P = 0.04 [9]
54 ESN Transmission P = 0.05* [10]
2605 Woman Transmission OR: 0.63 (95% CI 0.44-0.90) [11]
2996 High risk groups Transmission Risk = 0.30 (95% CI: 0.08-0.97) [12]
1252 MSM Transmission NS [13]
1200 HIV + vs control Transmission,
progression to AIDS
Both significant [14]
108 IDU Progression to AIDS NS [15]
127 Children Progression to AIDS Significant (p = 0.008) Effect is abrogated in case
of a SDF1-3′A genotype
[16]
1955 Hemophilia patients Progression to AIDS Significant [17]
512 Mother-child Transmission, progression to AIDS NS, significant [18]
These controversial data suggest that there might be additional factors beside the CCR5-delta32 genotype like SDF 1-3′ which contribute to the clinical outcome
of transmission and infection. (ESN = exposed seronegative, MSM = men having sex with men, IDU = injecting drug users, CI = confidence interval, OR = odds
ratio, NS = not significant) *only significant in heterosexuals.
Table 2 Results and characteristics of analyzed specimen
Specimen Gender Age CCR5 WT CCR5-delta32 heterozygous
1 N0014/05 m 19 +
2 N0015/05 f 53 +
3 N0023/05 m 24 +
4 N0024/05 f 21 +
5 N0031/05 m 25 +
6 N0035/05 m 21 +
7 N0091/06 m 30 +
8 N0094/06 m 20 +
9 N0103/06 m 32 +
10 N0106/06 m 23 +
11 N0118/07 f 28 +
12 N0136/07 f 29 +
13 N0153/07 f 29 +
14 N0158/07 m 25 +
15 N0163/07 f 23 +
16 N0200/08 f 74 +
17 N0204/08 f 85 +
18 N0305/09 f 28 +
19 N0312/09 f 34 +
CD34+ hematopoeitic progenitor cells for genotyping were obtained by bone
marrow aspiration.
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causing the protection from X4 transmission.
In addition, a certain protective effect in heterozygous
CCR5-delta32 carriers is also controversially discussed
(Table 1). It is well known that CCR5 receptor density
on the target cells determines the susceptibility against
transmission and that CCR5-delta32 heterozygotes have
a reduced receptor expression on the surface [5]. How-
ever, CCR5 is a dynamic receptor and several studies
have shown that CCR5 density in delta32 heterozygotes
could be similar to wild type individuals and therefore
the CCR5 surface expression might not be the single
protective factor [6,7].
Taken together, the mechanism of a near-perfect pro-
tection of complete CCR5 deficiency as well as the ob-
servation that HIV-infected CCR5-delta32 heterozygotes
may have a slower progression to AIDS has to be more
elucidated and might help identifying other key players
contributing to HIV pathogenesis [13,17].
Therefore, in this work we analyzed the gene expres-
sion patterns of CCR5-delta32 deletion in comparison to
wild type carriers, further, how the alteration change in
expression might contribute to the reduced clinical sus-
ceptibility and progression of HIV disease observed in
carriers of this mutation. This might improve the under-
standing of the connection between HIV pathogenesis
and immune system interaction of the underlying host.
Results and discussion
We screened CD34+ cells of 19 specimen contained
within a blood donor bank and identified 12 healthy
donors carrying wild type (WT) CCR5 while the re-
maining seven carried the CCR5-delta32 deletion alleleheterozygously (Table 2). Gene expression analysis re-
vealed 205 genes differentially expressed between WT
and heterozygous carriers of CCR5-delta32 mutation.
96 were found to be overexpressed in heterozygotes
(Additional file 1: Table S1) whereas the remaining 109
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respectively.
Further review of gene databases concerning the
known or proposed function of these genes regarding
HIV-1 infection revealed three genes in the WT group
and four genes in the CCR5-delta32 group with signifi-
cantly different overexpression profiles (Figures 1 and 2).
The theory that human host genes or polymorphic
variants of genes may influence transmission or the out-
come of HIV-1 infection goes back to the early 1980’s
[19]. Improved techniques using high throughput assays
provide insight into a detailed view in the pathogenesis
of HIV-1 and possible host or HIV-dependency factors
(HDF) [1]. Besides the well-characterized chemokine
entry mechanism there are several other allelic muta-
tions described in HDF genes such as IL10, IFNG, or
KIR3DS1 (together with HLA-Bw4). In addition, several
HLA subtypes have been found to be associated either
with delayed or accelerated progression to AIDS [20].
However, some phenomena remain unsolved. Especially
the role of the CCR5-delta32 deletion in transmission and
maintaining the infection is under investigation and there
are currently more open questions than answers. Recent
progress in HIV gene therapy revealed new insights of the
CCR5-delta32 deletion [21,22]. In the SB-728-T Sangamo
trial with anti CCR5 zinc-finger nuclease (ZFN) treated
lymphocytes in HIV patients, only one candidate with
a CCR5-delta32 heterozygous genotype in this group
achieved spontaneous virus control during HAART dis-
continuation. Taken into account that the CCR5 densityFigure 1 Results of the micro array gene expression analysis of 19 sp
associated with HIV-1 pathogenesis have been found to be overexpressed:
expression levels.in heterozygotes does not substantially differ from the
density in wild types, it is astonishing that an additional
knock down of less than a few percent of CCR5 expres-
sion by ZFNs has subsequently such a deep impact on
viral replication. Consequently it was not surprising
that Sangamo initiated a follow up trial especially for
carriers of the CCR5-delta32 genotype (SB-728-902-
Cohort 5) [23].
Most recently, the report of a long term control of HIV
in two patients receiving an allogeneic stem cell transplan-
tation (SCT) with a CCR5 wild type allo-graft (“Boston
patients”) has brought up new questions. These patients
showed a profound reduction of the viral reservoir, and
declining HIV antibody levels with ongoing engraftment
during the follow-up period of several years similar to the
“Berlin patient” [24]. Finally, in 2013 antiretroviral medica-
tion was discontinued in these patients and none of them
developed a rebound of HIV infection. Transplantation
has led to a replacement of the old immune system, anti-
retroviral therapy has protected the new engrafting cells
from re-infection, and probably GvHD has cleared residual
viral reservoirs in the host. Interestingly, both patients
were heterozygous for the CCR5-delta32 deletion [25].
Genes with higher expression in the wild type group
From 109 genes significantly overexpressed in the wild
type group, three were recognized to have an association
with HIV-1 (Table 3). Of these three, CXCR2 is
expressed in higher quantities in the wild type group.
Like CXCR1, CXCR2 acts as a receptor for interleukin 8ecimens. In the group of heterozygous CCR5-delta32 carriers 4 genes
A. U2AF65, B. CD30L, C. PRKACB, and D. TAP. Normalized arbitrary
Figure 2 Results of the micro array gene expression analysis of 19 specimens. In wild type sample there were 3 genes associated with
HIV-1 significantly overexpressed compared to heterozygous CCR5-delta32 carriers: A. TOP1, B. CXCR2, and C. SREBF2. Normalized arbitrary
expression levels.
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phocytes like CD56+/CD16+ NK-cells [26]. Both recep-
tors share intracellular cross-talk and in cells expressing
either CXCR1 or CXCR2, exposure to IL-8 leads to an
internalization of these receptors. This effect is signifi-
cant lower in cells expressing both of the receptors like
the CD56+/CD16+ NK-cells [27]. Additionally, binding
of IL-8 on the CXCR1 receptors causes an additional
cross-phosphorylation of both, CCR5 and CXCR4, re-
sulting in a decreased susceptibility against HIV-1. Only
the association of IL-8/CXCR1 and not IL-8/CXCR2
inherits this protective effect [28]. Most surprisingly in
this context is that the HIV-1 matrix protein p17 binds
to both, CXCR1 and CXCR2 in an IL-8-like manner
[29]. Taken together, the higher expression of CXCR2 in
the wild type group might have implications for the
p17HIV-1/IL-8 pathway of CXCR1 induced CCR5 inter-
nalization resulting in an altered susceptibility.Table 3 Three genes with a link to HIV-1 pathogenesis were f
type group
Significant higher Expression in CCR5 wild type samples
Gene Function (link to HIV-1)
TOP1 Synthesis of cDNA (in combination with RT transcription of
viral RNA to DNA)
CXCR2 Receptor for IL-8. Mediates neutrophil migration to sites of
inflammation. (binding side of p17HIV-1, cross-linked to CXCR1 an
indirectly cross-linked to CXCR1 mediated CCR5 internalisation)
SREBF2 Cholesterol metabolism (enhancing viral replication)
For TOP1 and SREBF2 there are reports that overexpression of these genes might h
beneficial effect was described in case of HIV-1 transmission. (transm. = transmissioTopoisomerase 1 (TOP1) is a 91 kDa enzyme that cri-
tically regulates the topological state of DNA during
transcription. TOP1 in association with reverse tran-
scriptase is most relevant for HIV cDNA synthesis [32].
Moreover, TOP1 is essential to directly interact with
HIV-1 nucleocapsid protein [33] In vitro assays with
overexpression of TOP1 led to an 5fold increase of
infective virions derived from these manipulated cells
[34]. Our finding that TOP1 was significantly under-
expressed in CCR5-delta32 samples than in wild type
samples could contribute to the clinical observation of
decreased rate of progression to AIDS in HIV-1-infected
heterozygous carriers.
Finally, cholesterol is known to play an essential role
in the life cycle of several enveloped viruses. Many of
these viruses manipulate host cholesterol metabolism to
facilitate their replication. The target gene of the sterol
regulatory element-binding protein 2 (SREBP2) whichound to be significant higher expressed in the CCR5 wild






ave a beneficial effect on HIV-1 infection. For CXCR2 overexpression this
n, repli. = replication).
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CCR5-delta32 group is TFII-I, a gene critical for HIV-1
transcription in activated T cells [31]. Experimental
knockdown of SREBP2 expression by small interfering
RNA (siRNA) resulted in a significant reduced viral rep-
lication. Consecutively, decreased expression of SREBP2
in CCR5-delta32 heterozygotes may contribute to bene-
fits of viral replication and progression to AIDS.
Genes with higher expression in the CCR5-delta32 group
In the CCR5-del32 group, 96 genes have been found to
be overexpressed and four of them had a link to HIV-1
infection (Table 4).
PRKACB was significantly higher expressed in the
CCR5-delta32 group. PRKACB is one of five human C
subunits of the PKA group which acts as a serine/threo-
nine kinase but only PRKACB together with PRKACA
and PRKX do act as functional protein kinases [39].
Concerning HIV-1 pathogenesis this kinase has been
described to be involved in infection such as activating
viral transcription of monocytes/macrophages in vitro,
or activation of T-cells in HIV-patients with ongoing
HAART [40,41]. Most interestingly is the transcrip-
tional regulation of CCR5 expression through a cAMP/
PKA/CREB dependent pathway. [42] The CCR5 pro-
moter region contains an cyclic AMP responsive ele-
ment which could be critical for the regulation of gene
expression [43]. Although authors could show that a
temporal increase of CCR5 expression could be me-
diated by PKA, the role of differentially regulated
PRKACB in HIV-1 pathogenesis still needs to be further
determined.
One possible mechanism of HIV-1 escape from immune
recognition and consecutive cytolysis is downregulation of
the MHC I expression. TAP as a transporter for antigen
presentation was overexpressed in the CCR5-delta32 car-
rier group. It is known that HIV-1 infection abolishes the
ability of cells to translocate antigenic peptides via TAP to
the endoplasmatic reticulum and thus indirectly abrogatesTable 4 Four genes were found with link to HIV-1 in the CCR5
Significant higher Expression in CCR5-delta32 samples
Gene Function (link to HIV-1)
U2AF65 Splicing factor (enhances with the polypyrimidine tract of the
splicosome of several HIV-1 genes)
CD30L Regulation immune response (elevated CD30 levels during
acute HIV-1 infection)
PRKACB Catalytic subunit of camp-dependent protein kinase
(coexpression with the HDF GliPR)
TAP Antigen presentation (HIV-1 abrogates TAP mediated peptide
transport to MHC I presentation)
Only for TAP there was a beneficial effect pre-described in terms of viral transmissio
beneficial effect available. (transm. = transmission, repli. = replication).peptides from MHC I presentation [38]. Overexpression
of TAP in heterozygotes might partially compensate this
HIV-induced inhibition leading to an enhanced clearance
of infected cells and indirectly to a decreased susceptibility
in this group.
U2AF65 is a 65 kDa auxiliary factor of pre-mRNA spli-
cing and contains a sequence-specific RNA-binding region
with 3′ RNA recognition motifs and an Arg/Ser-rich
domain necessary for splicing. The spliced mRNA species
in HIV-1 infected cells are env/vpu, nef, rev, vpr, and vif.
The binding of a 35 kDa subunit stabilizes the binding
of U2AF65 with the polypyrimidine tract (PPT) of in-
trons during spliceosome assembly [35,44]. However,
there are no reports that altered expression of U2AF65
contributes to HIV-1 viral progression or susceptibility
of transmission.
CD30L is mainly expressed in high levels on activated
T cells interacting either with membrane bound CD30
from B or T lymphocytes or soluble CD30. Soluble CD30
has been described to be expressed in high amounts du-
ring acute HIV-1 infection [36]. Recently, it has been
reported that specified CD4 and CD8 T cell clones are
capable of producing T helper (Th)2-type cytokines,
which release soluble CD30 into the circulation [45]. The
general function of the CD30/CD30L interaction is still
unsolved. It has been suggested that this interaction pro-
motes secondary humoral immune responses. However,
an in vivo test system with CD30−/− knockout mice or
anti CD30L antibodies have led to conflicting results [46].
Taken together, there is no convincing explanation
whether the CD30L overexpression in CCR5-delta32 hete-
rozygotes may contribute to a potential benefit in these
patients or not.
Conclusions
We identified 7 genes previously found to be associated
with HIV-1 pathogenesis and furthermore were differen-
tially expressed in CCR5 wild type and CCR5-delta32
heterozygous individuals. Out of these two, CXCR2 and-delta32 heterozygous group






n. For the other three genes there are currently no data concerning a
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transmission, and two genes, TOP1 and SREBF2, may be
favorable in terms of replication and disease progression
in heterozygous CCR5-delta32 carriers. Concerning the
other three genes, there was no evidence of a beneficial
effect described so far. The clinical relevance of these
findings should be further tested in prospective studies.
Methods
Specimen
Input material for this analysis were immunomagneti-
cally purified CD34+ cells from bone marrow aspiration
of 19 healthy volunteers, 9 male 10 female, aged 19–85
(median 25) years. All donors gave written informed
consent before investigation. Prior to CD34+ selection,
mononuclear cells were isolated by density gradient cen-
trifugation through Ficoll-Hypaque (Biochrom, Berlin,
Germany). The study protocol was approved by the Ethical
committee II, Medical Faculty Mannheim, Heidelberg
University Institutional Review Board.
CCR5 genotyping analysis
Genomic DNA was extracted from heparinised peri-
pheral blood monocytes (PBMC) of the donors with the
QIAGEN-Blood-Midi-Kit (Qiagen, Germany). Scree-
ning of the donors for the CCR5-delta32-allele was per-
formed with a genomic PCR using primers flanking the
site of the deletion (forward: 5′-CTCCCAGGAATCAT
CTTTACC-3′, reverse: 5′-TCATTTCGACACCGAAG
CAG-3′) leading to a PCR fragment of 200 base pairs
(bp) for the CCR5-allele and of 168 bp in case of a
delta32 deletion. Results were confirmed by allele spe-
cific PCR and by direct sequencing using the BigDye®-
Terminator-1.1.-Cycle-Sequencing-Kit (Applied Biosystems,
Germany). Sequences were analyzed using the Vector-
NTI-Contig-Express-software (Invitrogen, Germany).
RNA preparation and array based gene expression
analysis
Total RNA was extracted from purified CD34+
hematopoietic progenitor cells using TRIzol (Invitrogen,
Karlsruhe, Germany) according to the manufacturer’s
protocol. The quality of RNA was determined by the 2100
Bioanalyzer system (Agilent Technologies, Waldbronn,
Germany) and only samples showing no RNA-degradation
were included into the analysis. Oligonucleotide microar-
rays (HG-U133plus 2.0, Affymetrix Inc., Santa Clara,
CA) were hybridized as described previously [47]. Data
analysis was performed by the Microarray Suite 5.0
(Affymetrix), and the Genespring software 4.2 (Silicon
Genetics, Redwood City, CA). The quality control pa-
rameters were in accordance to the MIAME consensus
criteria for micro array data with a present call rate of at
least 25% [48]. Previously, our group has shown a closecorrelation of micro-array data compared to quantita-
tive PCR methods in the same sample [49].
Statistics
All samples were normalized with expression values raised
to an arbitrary value of 1. Only expression values which
reach a present call rate of 75% have been used. Only
genes with a significant three-fold difference of expression
(p < 0.05) between the CCR5 wild type and the CCR5-
delta32 group were eligible for further statistical analysis.
Expression analysis of the different groups was performed
by using the Mann Whitney test.
Additional file
Additional file 1: Table S1. Results of the Affymetrix Micro Array Assay.
Only expressions with 3fold difference, present call rate of 75%, and
p < 0.05 have been noted.
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